AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Medicine Advances Article
PDF (10.8 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Original Article | Open Access

Proteomic characteristics of lung adenocarcinoma tumors that are small but highly invasive

Zhenbin Qiu1,2,3, Xiongwen Yang1,2,3, Jin Xia1,2,3, Chao Zhang1,2,3, Wenfang Tang4, Xiangpeng Chu1,2, Rui Fu1,2,3, Xuening Yang1,2, Xuchao Zhang1,2, Yilong Wu1,2, Wenzhao Zhong1,2,3( )
School of Medicine, South China University of Technology, Guangzhou, China
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China
Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China
Department of Cardiovascular Surgery, Zhongshan People's Hospital, Zhongshan, China

Zhenbin Qiu, Xiongwen Yang and Jin Xia contributed equally.

Show Author Information

Graphical Abstract

Comprehensive proteomics characterization analyzed of lung adenocarcinom (LUAD) tissues and paired normal tissues were selected from 25 patients with stage pT1bN2M0 (group of metastases [GM]) and 27 patients with stage T2b‐3N0M0 (group of large primary focus, GL). The activation of the extracellular matrix and intracellular signal transduction might be the driving mechanisms for early lymph node metastasis. Proteome‐based stratification of LUAD revealed three subtypes (S‐I, S‐II, and S‐III) related to different clinical and molecular features.

Abstract

Background

Understanding the molecular mechanism of early lymph node metastasis among lung adenocarcinoma (LUAD) is essential for developing novel therapeutic agents. Proteomic studies helped generate molecular landscape for LUAD. However, the molecular basis of early lymph node metastases remains unknown in patients with LUAD.

Methods

Surgically resected LUAD tissues and paired normal tissues were selected from 25 patients with stage pT1bN2M0 (group of metastases [GM]) and 27 patients with stage T2b‐3N0M0 (group of large primary focus, GL) who had not undergone any anti‐tumor treatment. 4D‐Label‐free proteomics sequencing was performed among these tissues. The clinicopathological information was retrieved from the electronic medical record system in Guangdong Provincial People's Hospital.

Results

Compared with GL tumor tissue, 89 upregulated and 155 downregulated proteins were identified in GM tumor tissue. Upregulated proteins of GM were enriched in the ECM‐receptor interaction and PI3K‐AKT pathway under Kyoto Encyclopedia of Genes and Genomes enrichment analysis. And then, the median disease‐free survival (DFS) of GM phenotype patients was used as the cut‐off value, and GM was divided into two groups with significantly different survival outcomes (DFS good vs. DFS Poor: DFS: p < 0.0001; overall survival: p = 0.0017). All members of the Microchromosome maintenance protein family were highly expressed in the DFS‐poor group, especially MCM2. Proteome‐based stratification of LUAD revealed three subtypes (S‐2, S‐2, and S‐3) related to different clinical and molecular features. S‐3 had higher catabolism‐related pathways enriched, such as amino sugar and nucleotide sugar metabolism and fructose and mannose metabolism, which has the worst prognosis (S1 vs. S2 vs. S3, RFS: p = 0.042).

Conclusions

Proteomics analyses revealed that the activation of the extracellular matrix and intracellular signal transduction might be the driving mechanisms for early lymph node metastasis. Higher expressed cell proliferation related pathways of early lymph node metastatic LUAD may accelerate the recurrence after curative surgery. Three proteomic subgroups of LUAD with distinct molecular and clinical characteristics were identified, the one of which characterized by enrichment of catabolism‐related pathways displayed the worst survival data.

Keywords

lung adenocarcinomaproteomicslymph nodemetastasisfocal adhesion

Electronic Supplementary Material

Download File(s)
med-1-4-340-ESM1.zip (790.2 KB)
med-1-4-340-ESM2.docx (17.9 KB)

References

[1]

Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. Ann. Glob. Heath. 2019;85(1):8. https://doi.org/10.5334/aogh.2419
Crossref Google Scholar
[2]

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492
Crossref Google Scholar
[3]

Karacz CM, Yan J, Zhu H, Gerber DE. Timing, sites, and correlates of lung cancer recurrence. Clin Lung Cancer. 2020;21(2):127–35.e3. https://doi.org/10.1016/j.cllc.2019.12.001
Crossref Google Scholar
[4]

Herbst RS, Morgensztern D, Boshoff C. The biology and management of non‐small cell lung cancer. Nature. 2018;553(7689):446–54. https://doi.org/10.1038/nature25183
Crossref Google Scholar
[5]

Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ, Wu YL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299–311. https://doi.org/10.1016/S0140-6736(16)30958-8
Crossref Google Scholar
[6]

Albaba H, Lim C, Leighl NB. Economic considerations in the use of novel targeted therapies for lung cancer: review of current literature. Pharmacoeconomics. 2017;35(12):1195–209. https://doi.org/10.1007/s40273-017-0563-8
Crossref Google Scholar
[7]

Chen YJ, Roumeliotis TI, Chang YH, Chen CT, Han CL, Lin MH, et al. Proteogenomics of non‐smoking lung cancer in East Asia delineates molecular signatures of pathogenesis and progression. Cell. 2020;182(1):226.e17–244.e17. https://doi.org/10.1016/j.cell.2020.06.012
Crossref Google Scholar
[8]

Gillette MA, Satpathy S, Cao S, Dhanasekaran SM, Vasaikar SV, Krug K, et al. Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma. Cell. 2020;182(1):200.e35–225.e35. https://doi.org/10.1016/j.cell.2020.06.013
Crossref Google Scholar
[9]

Xu JY, Zhang C, Wang X, Zhai L, Ma Y, Mao Y, et al. Integrative proteomic characterization of human lung adenocarcinoma. Cell. 2020;182(1):245.e17–261.e17. https://doi.org/10.1016/j.cell.2020.05.043
Crossref Google Scholar
[10]

Clarke MR, Landreneau RJ, Finkelstein SD, Wu TT, Ohori P, Yousem SA. Extracellular matrix expression in metastasizing and nonmetastasizing adenocarcinomas of the lung. Hum Pathol. 1997;28(1):54–9. https://doi.org/10.1016/s0046-8177(97)90279-3
Crossref Google Scholar
[11]

Polio SR, Stasiak SE, Jamieson RR, Balestrini JL, Krishnan R, Parameswaran H. Extracellular matrix stiffness regulates human airway smooth muscle contraction by altering the cell‐cell coupling. Sci Rep. 2019;9(1):9564. https://doi.org/10.1038/s41598-019-45716-9
Crossref Google Scholar
[12]

Lu T, Yang X, Shi Y, Zhao M, Bi G, Liang J, et al. Single‐cell transcriptome atlas of lung adenocarcinoma featured with ground glass nodules. Cell Discov. 2020;6(1):69. https://doi.org/10.1038/s41421-020-00200-x
Crossref Google Scholar
[13]

Williams GH, Stoeber K. The cell cycle and cancer. J Pathol. 2012;226(2):352–64. https://doi.org/10.1002/path.3022
Crossref Google Scholar
[14]

Boyer AS, Walter D, Sørensen CS. DNA replication and cancer: from dysfunctional replication origin activities to therapeutic opportunities. Semin Cancer Biol. 2016;37‐38:16–25. https://doi.org/10.1016/j.semcancer.2016.01.001
Crossref Google Scholar
[15]

Discher DE, Mooney DJ, Zandstra PW. Growth factors, matrices, and forces combine and control stem cells. Science. 2009;324(5935):1673–7. https://doi.org/10.1126/science.1171643
Crossref Google Scholar
[16]

Rath N, Morton JP, Julian L, Helbig L, Kadir S, McGhee EJ, et al. ROCK signaling promotes collagen remodeling to facilitate invasive pancreatic ductal adenocarcinoma tumor cell growth. EMBO Mol Med. 2017;9(2):198–218. https://doi.org/10.15252/emmm.201606743
Crossref Google Scholar
[17]

Liang Y, Xia W, Zhang T, Chen B, Wang H, Song X, et al. Upregulated collagen COL10A1 remodels the extracellular matrix and promotes malignant progression in lung adenocarcinoma. Front Oncol. 2020;10:573534. https://doi.org/10.3389/fonc.2020.573534
Crossref Google Scholar
[18]

Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol. 2005;6(1):56–68. https://doi.org/10.1038/nrm1549
Crossref Google Scholar
[19]

Zhao X, Guan JL. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv Drug Deliv Rev. 2011;63(8):610–5. https://doi.org/10.1016/j.addr.2010.11.001
Crossref Google Scholar
[20]

Liang J, Li H, Han J, Jiang J, Wang J, Li Y, et al. Mex3a interacts with LAMA2 to promote lung adenocarcinoma metastasis via PI3K/AKT pathway. Cell Death Dis. 2020;11(8):614. https://doi.org/10.1038/s41419-020-02858-3
Crossref Google Scholar
[21]

Park BJ, Kim TH, Shin S, Kim HK, Choi YS, Kim J, et al. Recommended change in the N descriptor proposed by the international association for the study of lung cancer: a validation study. J Thorac Oncol. 2019;14(11):1962–9. https://doi.org/10.1016/j.jtho.2019.07.034
Crossref Google Scholar
[22]

Yeeles JTP, Deegan TD, Janska A, Early A, Diffley JFX. Regulated eukaryotic DNA replication origin firing with purified proteins. Nature. 2015;519(7544):431–5. https://doi.org/10.1038/nature14285
Crossref Google Scholar
[23]

Hashimoto K, Araki K, Osaki M, Nakamura H, Tomita K, Shimizu E, et al. MCM2 and Ki‐67 expression in human lung adenocarcinoma: prognostic implications. Pathobiology. 2004;71(4):193–200. https://doi.org/10.1159/000078673
Crossref Google Scholar
[24]

Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147(2):275–92. https://doi.org/10.1016/j.cell.2011.09.024
Crossref Google Scholar
[25]

Tang WF, Wu M, Bao H, Xu Y, Lin JS, Liang Y, et al. Timing and origins of local and distant metastases in lung cancer. J Thorac Oncol. 2021;16(7):1136–48. https://doi.org/10.1016/j.jtho.2021.02.023
Crossref Google Scholar
[26]

Suhail Y, Cain MP, Vanaja K, Kurywchak PA, Levchenko A, Kalluri R, et al. Systems biology of cancer metastasis. Cell Syst. 2019;9(2):109–27. https://doi.org/10.1016/j.cels.2019.07.003
Crossref Google Scholar
[27]

Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70. https://doi.org/10.1038/nature11412
Crossref Google Scholar
[28]

Garcia SN, Guedes RC, Marques MM. Unlocking the potential of HK2 in cancer metabolism and therapeutics. Curr Med Chem. 2019;26(41):7285–322. https://doi.org/10.2174/0929867326666181213092652
Crossref Google Scholar
[29]

Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–33. https://doi.org/10.1126/science.1160809
Crossref Google Scholar
Medicine Advances
Volume 1 Issue 4,
December 2023
Pages 340-352
DOI: 10.1002/med4.38
Cite this article:
Qiu Z, Yang X, Xia J, et al. Proteomic characteristics of lung adenocarcinoma tumors that are small but highly invasive. Medicine Advances, 2023, 1(4): 340-352. https://doi.org/10.1002/med4.38

481

Views

31

Downloads

0

Crossref

Altmetrics
Received: 11 May 2023
Accepted: 09 September 2023
Published: 27 November 2023
© 2023 The Authors. Tsinghua University Press.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
Return